| scholarly article | Q13442814 |
| P50 | author | Adrián Llerena | Q56419301 |
| P2093 | author name string | Lindström L | |
| Bertilsson L | |||
| Dahl ML | |||
| Bondesson U | |||
| P2860 | cites work | A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. | Q33667784 |
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Polymorphic hydroxylation of Debrisoquine in man. | Q34057031 | ||
| Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin | Q34241704 | ||
| Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 | Q35275118 | ||
| Clozapine. A novel antipsychotic agent | Q36485618 | ||
| Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia | Q38037996 | ||
| Genetically variable metabolism of antidepressants and neuroleptic drugs in man. | Q40710734 | ||
| Role of genetic polymorphism in psychopharmacology--an update | Q40840711 | ||
| Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs | Q41773246 | ||
| Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans | Q43607538 | ||
| Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection | Q43794493 | ||
| MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation | Q48183426 | ||
| Is the sigma opiate receptor a proadifen-sensitive subform of cytochrome P-450? | Q48944016 | ||
| The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins | Q49113663 | ||
| SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorpan and σ ligands to guinea pig brain | Q53867774 | ||
| Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype | Q57586064 | ||
| Exchange of aromatically bound halogen for OH- and SCH3-groups in metabolising clozapine in the human organism (author's transl) | Q67022219 | ||
| Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection | Q67550135 | ||
| Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors | Q67553978 | ||
| Polymorphic debrisoquin hydroxylation in 757 Swedish subjects | Q67928181 | ||
| Clinical pharmacokinetics of clozapine in chronic schizophrenic patients | Q67989786 | ||
| The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6 | Q68071363 | ||
| Multiple-dose pharmacokinetics of clozapine in patients | Q68853598 | ||
| S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin | Q69610224 | ||
| Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings | Q69649340 | ||
| Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age | Q69795312 | ||
| Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype | Q70123367 | ||
| Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man | Q70219763 | ||
| The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e) (1,4)diazepine (clozapine) in mice, dogs and human subjects | Q70707284 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 71-74 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms | |
| P478 | volume | 37 |
| Q80967258 | A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment |
| Q38156174 | A therapeutic interaction between cimetidine and clozapine: case study and review of the literature |
| Q57719513 | Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients |
| Q37012022 | CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits |
| Q40950299 | Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine |
| Q33916981 | Clinically significant pharmacokinetic interactions between dietary caffeine and medications |
| Q43201721 | Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test |
| Q41236862 | Clozapine plasma level monitoring: current status |
| Q43986056 | Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables |
| Q31917457 | Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial |
| Q43706439 | Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations |
| Q33810893 | Cytochrome P450 and therapeutic drug monitoring with respect to clozapine |
| Q34612118 | Cytochrome P450 polymorphisms and response to antipsychotic therapy. |
| Q34347496 | Cytochrome P4502D6 genotype does not determine response to clozapine |
| Q34706835 | Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? |
| Q43630883 | Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection |
| Q33697379 | Drug metabolism and atypical antipsychotics |
| Q33157593 | Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects |
| Q28270486 | Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 |
| Q41172369 | Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism |
| Q35096587 | Interactions between the cytochrome P450 system and the second-generation antipsychotics |
| Q38616806 | Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. |
| Q47737546 | Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development |
| Q36703845 | Metabolic drug interactions with newer antipsychotics: a comparative review. |
| Q33668212 | Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs |
| Q52041523 | Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. |
| Q64122673 | PharmGKB summary: clozapine pathway, pharmacokinetics |
| Q37344782 | Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations |
| Q38154175 | Pharmacogenetics in schizophrenia: a review of clozapine studies |
| Q28252209 | Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response |
| Q35802661 | Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance |
| Q33858281 | Potential role of patients' CYP3A-status in clozapine pharmacokinetics. |
| Q33954264 | Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
| Q41382487 | Will routine therapeutic drug monitoring have a place in clozapine therapy? |
Search more.